Aytu BioPharma, Inc. (AYTU)
USD 1.01
(1.0%)
USD 1.01
(1.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 118.09 Million USD | -13.46% |
| 2023 | 136.46 Million USD | -0.84% |
| 2022 | 137.62 Million USD | -48.2% |
| 2021 | 265.66 Million USD | 73.83% |
| 2020 | 152.83 Million USD | 340.18% |
| 2019 | 34.72 Million USD | 64.87% |
| 2018 | 21.06 Million USD | 40.41% |
| 2017 | 14.99 Million USD | -38.39% |
| 2016 | 24.34 Million USD | 33.56% |
| 2015 | 18.22 Million USD | 51.69% |
| 2014 | 12.01 Million USD | 124174.48% |
| 2013 | 9669.00 USD | -23.55% |
| 2012 | 12.64 Thousand USD | -44.62% |
| 2011 | 22.83 Thousand USD | -15.7% |
| 2010 | 27.09 Thousand USD | -35.27% |
| 2009 | 41.85 Thousand USD | -43.5% |
| 2008 | 74.07 Thousand USD | 24.13% |
| 2007 | 59.67 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 118.09 Million USD | -8.36% |
| 2024 Q3 | 128.86 Million USD | -1.82% |
| 2024 Q2 | 131.24 Million USD | -1.23% |
| 2024 Q1 | 132.88 Million USD | -2.62% |
| 2023 Q3 | 147.21 Million USD | 4.09% |
| 2023 Q2 | 141.43 Million USD | -5.71% |
| 2023 Q4 | 136.46 Million USD | -7.3% |
| 2023 Q1 | 150 Million USD | 8.99% |
| 2023 FY | 136.46 Million USD | -0.84% |
| 2022 Q1 | 227.72 Million USD | -14.28% |
| 2022 FY | 137.62 Million USD | -48.2% |
| 2022 Q4 | 137.62 Million USD | -18.48% |
| 2022 Q3 | 168.82 Million USD | -24.57% |
| 2022 Q2 | 223.82 Million USD | -1.71% |
| 2021 Q4 | 265.66 Million USD | -2.17% |
| 2021 FY | 265.66 Million USD | 73.83% |
| 2021 Q1 | 141.27 Million USD | -7.57% |
| 2021 Q2 | 166.74 Million USD | 18.03% |
| 2021 Q3 | 271.55 Million USD | 62.86% |
| 2020 Q2 | 74.47 Million USD | 140.06% |
| 2020 Q3 | 158.95 Million USD | 113.42% |
| 2020 FY | 152.83 Million USD | 340.18% |
| 2020 Q4 | 152.83 Million USD | -3.85% |
| 2020 Q1 | 31.02 Million USD | -10.65% |
| 2019 Q1 | 17.98 Million USD | -14.6% |
| 2019 FY | 34.72 Million USD | 64.87% |
| 2019 Q3 | 38.33 Million USD | -9.58% |
| 2019 Q4 | 34.72 Million USD | -9.43% |
| 2019 Q2 | 42.39 Million USD | 135.75% |
| 2018 FY | 21.06 Million USD | 40.41% |
| 2018 Q4 | 21.06 Million USD | -9.9% |
| 2018 Q2 | 18.85 Million USD | -11.24% |
| 2018 Q1 | 21.24 Million USD | 41.65% |
| 2018 Q3 | 23.37 Million USD | 23.95% |
| 2017 Q3 | 15.91 Million USD | -25.99% |
| 2017 Q2 | 21.5 Million USD | 6.46% |
| 2017 FY | 14.99 Million USD | -38.39% |
| 2017 Q1 | 20.2 Million USD | -17.02% |
| 2017 Q4 | 14.99 Million USD | -5.77% |
| 2016 Q2 | 24.4 Million USD | 14.28% |
| 2016 Q4 | 24.34 Million USD | 10.72% |
| 2016 FY | 24.34 Million USD | 33.56% |
| 2016 Q1 | 21.35 Million USD | 17.19% |
| 2016 Q3 | 21.98 Million USD | -9.93% |
| 2015 Q4 | 18.22 Million USD | 78.67% |
| 2015 FY | 18.22 Million USD | 51.69% |
| 2015 Q3 | 10.2 Million USD | 91392.96% |
| 2015 Q2 | 11.15 Thousand USD | 102.25% |
| 2015 Q1 | 5513.00 USD | -59.15% |
| 2014 Q3 | 5630.00 USD | -21.41% |
| 2014 Q4 | 13.49 Thousand USD | 139.72% |
| 2014 Q1 | 9669.00 USD | 2.41% |
| 2014 FY | 12.01 Million USD | 124174.48% |
| 2014 Q2 | 7164.00 USD | -25.91% |
| 2013 Q3 | 13.11 Thousand USD | 10.42% |
| 2013 Q4 | 9441.00 USD | -28.0% |
| 2013 FY | 9669.00 USD | -23.55% |
| 2013 Q1 | 12.64 Thousand USD | -9.83% |
| 2013 Q2 | 11.87 Thousand USD | -6.1% |
| 2012 Q3 | 16.28 Thousand USD | -13.45% |
| 2012 Q2 | 18.81 Thousand USD | -17.6% |
| 2012 FY | 12.64 Thousand USD | -44.62% |
| 2012 Q1 | 22.83 Thousand USD | -19.84% |
| 2012 Q4 | 14.02 Thousand USD | -13.89% |
| 2011 Q4 | 28.48 Thousand USD | 0.17% |
| 2011 FY | 22.83 Thousand USD | -15.7% |
| 2011 Q3 | 28.44 Thousand USD | 13.81% |
| 2011 Q2 | 24.98 Thousand USD | -7.76% |
| 2011 Q1 | 27.09 Thousand USD | -25.21% |
| 2010 Q2 | 29.61 Thousand USD | -29.24% |
| 2010 Q3 | 26.03 Thousand USD | -12.08% |
| 2010 FY | 27.09 Thousand USD | -35.27% |
| 2010 Q4 | 36.22 Thousand USD | 39.13% |
| 2010 Q1 | 41.85 Thousand USD | -2.9% |
| 2009 Q1 | 74.07 Thousand USD | -9.79% |
| 2009 Q4 | 43.1 Thousand USD | 1.29% |
| 2009 Q3 | 42.54 Thousand USD | -20.07% |
| 2009 Q2 | 53.23 Thousand USD | -28.14% |
| 2009 FY | 41.85 Thousand USD | -43.5% |
| 2008 Q1 | 59.67 Thousand USD | -11.78% |
| 2008 FY | 74.07 Thousand USD | 24.13% |
| 2008 Q4 | 82.1 Thousand USD | -13.38% |
| 2008 Q2 | 107.5 Thousand USD | 80.15% |
| 2008 Q3 | 94.78 Thousand USD | -11.83% |
| 2007 Q4 | 67.63 Thousand USD | 0.0% |
| 2007 FY | 59.67 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -53.671% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 86.942% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -105.676% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 92.499% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -331.84% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -331.84% |
| SCYNEXIS, Inc. | 128.41 Million USD | 8.034% |
| Safety Shot Inc | 12.7 Million USD | -829.21% |
| Alpha Teknova, Inc. | 128.58 Million USD | 8.159% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 89.671% |
| Bright Green Corporation | 17.4 Million USD | -578.588% |
| Dynavax Technologies Corporation | 997.09 Million USD | 88.156% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 42.616% |
| Cosmos Health Inc. | 66.29 Million USD | -78.134% |
| PainReform Ltd. | 9.93 Million USD | -1089.275% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -410.636% |
| Embecta Corp. | 1.21 Billion USD | 90.275% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 83.785% |
| Procaps Group, S.A. | 460.18 Million USD | 74.338% |
| Theratechnologies Inc. | 77.76 Million USD | -51.854% |
| Harrow Health, Inc. | 311.75 Million USD | 62.119% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -692.956% |
| Biofrontera Inc. | 27.93 Million USD | -322.795% |
| DURECT Corporation | 45.18 Million USD | -161.336% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 91.618% |
| Cronos Group Inc. | 1.13 Billion USD | 89.588% |
| OptiNose, Inc. | 107.72 Million USD | -9.622% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 74.931% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -111.076% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -412.406% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 74.329% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -890.881% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -44.413% |
| Radius Health, Inc. | 1.71 Billion USD | 93.118% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -121.621% |
| ProPhase Labs, Inc. | 91.92 Million USD | -28.466% |
| Phibro Animal Health Corporation | 982.18 Million USD | 87.976% |
| Procaps Group S.A. | 460.18 Million USD | 74.338% |
| Alvotech | 950.09 Million USD | 87.57% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -172.68% |
| Viatris Inc. | 47.68 Billion USD | 99.752% |
| Rockwell Medical, Inc. | 52.17 Million USD | -126.353% |
| SIGA Technologies, Inc. | 254.83 Million USD | 53.658% |
| Tilray Brands, Inc. | 4.33 Billion USD | 97.276% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 56.853% |
| Shineco, Inc. | 84.17 Million USD | -40.29% |
| PetIQ, Inc. | 868.22 Million USD | 86.398% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -1299.527% |
| Incannex Healthcare Limited | 17.04 Million USD | -592.761% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 96.368% |
| Alimera Sciences, Inc. | 153.52 Million USD | 23.077% |
| Silver Spike Investment Corp. | 88.57 Million USD | -33.326% |
| Assertio Holdings, Inc. | 286.41 Million USD | 58.768% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1884.211% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -249.437% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -277.989% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -791.449% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 54.775% |
| Hempacco Co., Inc. | 18.04 Million USD | -554.517% |
| Talphera, Inc. | 20.39 Million USD | -479.039% |
| Alvotech | 950.09 Million USD | 87.57% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 70.924% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 92.848% |
| Currenc Group, Inc. | 141.49 Million USD | 16.535% |
| Kamada Ltd. | 351.96 Million USD | 66.447% |
| Indivior PLC | 1.95 Billion USD | 93.948% |
| Evoke Pharma, Inc. | 7.06 Million USD | -1570.711% |
| Flora Growth Corp. | 23.62 Million USD | -399.852% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -791.449% |
| Evolus, Inc. | 188.99 Million USD | 37.515% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 90.772% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 92.194% |
| Akanda Corp. | 8.83 Million USD | -1235.917% |